Molecular Oncology
Our Molecular Oncology division uses molecular testing to identify the genetic abnormalities that drive cancer and allows for targeted therapy and a better understanding of the patient's prognosis
This testing revolutionizes the standard of patient care, changing how diseases are diagnosed and treated. HNL Lab Medicine's Molecular Oncology department utilizes sophisticated molecular techniques, including next-generation sequencing for comprehensive profiling of both solid tumors and hematologic malignancies.
Common Molecular Oncology Tests
NGS Solid Tumor Panel -523 genes; DNA & RNA Sequencing; sub-panels available on request (Lung, Colon, GIST, Melanoma etc.)
NGS Solid Tumor with TMB and MSI The NGS Solid Tumor with TMB and MSI panel offers a comprehensive assessment of key biomarkers to enhance treatment outcomes and optimize patient care. In addition to identifying relevant DNA and RNA variants implicated in various tumor types, it accurately measures key current immuno-oncology biomarkers: microsatellite instability (MSI) and tumor mutational burden (TMB).
- Turnaround Time - 14 Days
- 523 genes for DNA
- 55 genes for RNA
- 99% Analytical Sensitivity
Genes tested
Hotspot Genes (87) | Full-Length Genes (48) | Copy Number Genes (43) | Gene Fusions (Inter- and Intra-genic) |
|---|---|---|---|
AKT1, AKT2, AKT3, ALK, AR, ARAF, AXL, BRAF, BTK, CBL, CCND1, CDK4, CDK6, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERCC2, ESR1, EZH2, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, H3F3A, HIST1H3B, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KIT, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAPK1, MAX, MDM4, MED12, MET, MTOR, MYC, MYCN, MYD88, NFE2L2, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPP2R1A, PTPN11, RAC1, RAF1, RET, RHEB, RHOA, ROS1, SF3B1, SMAD4, SMO, SPOP, SRC, STAT3, TERT, TOP1, U2AF1, XPO1 | ARID1A, ATM, ATR, ATRX, BAP1, BRCA1, BRCA2, CDK12, CDKN1B, CDKN2A, CDKN2B, CHEK1, CREBBP, FANCA, FANCD2, FANCI, FBXW7, MLH1, MRE11A, MSH2, MSH6, NBN, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, PALB2, PIK3R1, PMS2, POLE, PTCH1, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RB1, RNF43, SETD2, SLX4, SMARCA4, SMARCB1, STK11, TP53, TSC1, TSC2 | AKT1, AKT2, AKT3, ALK, AR, AXL, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPARG, RICTOR, TERT | AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT |
BRAF p.V600E, p.V600K, p.V600R
- Turnaround Time - 7 days
NGS Myeloid Panel – 69 genes; DNA & RNA sequencing
- Turnaround Time – 14 days
- Variants tested: Single Nucleotide Variants (SNV), Small Insertions/Deletions (Indels), Fusions
Genes tested
Hotspot Genes (23) | Full Genes (17) | Fusion Driver Genes (29) | Expression Genes (5) | Expression Control Genes (5) |
|---|---|---|---|---|
| ABL1, KRAS, BRAF, MPL, CBL, MYD88, CSF3R, NPM1, DNMT3A, NRAS, FLT3, PTPN11, GATA2, SETBP1, HRAS, SF3B1, IDH1, SRSF2, IDH2, U2AF1, JAK2, WT1, KIT | ASXL1, PRPF8, BCOR, RB1, CALR, RUNX1, CEBPA, SH2B3, ETV6, STAG2, EZH2, TET2, IKZF1, TP53, NF1, ZRSR2, PHF6 | ABL1, HMGA2, NUP214, ALK, JAK2, PDGFRA, BCL2, KMT2A (MLL), RARA, CCND1, MECOM, RBM15, CREBBP, MET, RUNX1, EGFR, MLLT10, TCF3, ETV6, MLLT3, TFE3, FGFR1, MYBL1, FGFR2, MYH11, FUS, NTRK3 | BAALC, MECOM, MYC, SMC1A, WT1 | EIF2B1, FBXW2, PSMB2, PUM1, TRIM27 |
FLT3-ITD and FLT3-TKD
- Turnaround Time – 2 days
BCR/ABL1 Quantitative
- Turnaround Time – 4 days
JAK2 p.V617F
- Turnaround Time –4 days
Related Resources